Palvella Therapeutics Publishes July 2026 Corporate Presentation
Palvella Therapeutics disclosed a corporate presentation covering first-in-disease therapies for rare diseases. This filing serves to inform shareholders of the company's strategic outlook and asset pipeline.
View filing at SEC.gov →